Genmab: Epcoritamab added to NCCN guidelines for ‘B-Cell Lymphomas’

Genmab (GMAB) announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for “B-cell Lymphomas” for third-line and subsequent therapy for patients with diffuse large B-cell lymphoma , including patients with disease progression after transplant or chimeric antigen receptor or CAR T-cell therapy and as a Category 2A, preferred regimen for patients with histologic transformation of indolent lymphomas to DLBCL and no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy. This recommendation is based on uniform NCCN consensus that the intervention is appropriate.i Epcoritamab is being co-developed by Genmab and AbbVie (ABBV) as part of the companies’ oncology collaboration. Epcoritamab-bysp was recently approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial. “The NCCN Guidelines are a resource for treating various types of cancer and providing healthcare providers with information for making informed treatment decisions,” said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. “We are pleased that the NCCN has updated its Guidelines to include epcoritamab in a speedy manner.”